LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...

We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...

The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...

French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income ...

Sarrah Strimel Bentley is an optimist – even when it comes to her journey with early breast cancer. The new mother and philanthropist discusses why she’s empowered to live a happy and healthy life.

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth.

French pharma company Sanofi has joined Ely Lilly and Johnson & Johnson in a challenge to the U.S.'s 340B drug discount ...

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the ...

Old Town Med Spa is among those being accused of using false advertising and deceptive marketing practices to sell ...

The Players Era Festival, which will be held in Las Vegas next week, is set to announce a presenting sponsor lineup or Eli Lilly Company, MGM Resorts, and Starbucks.

Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.